All In Biotech

Drug Trial Radar · NCT01429116

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

An Extension Open-Label Safety Study of a 24-month 20 mg Dose Regimen of Tasimelteon for the Treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception Who Have Enrolled in Other Tasimelteon Clinical Trials

Last checked: Nov 19, 2026Latest source record: Apr 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 2011

Primary completion

Jan 2015

Study completion Jan 2015

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 5, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of tasimelteon in male and female patients who suffer from Non-24-Hour Sleep-Wake Disorder.

Conditions

  • Non-24-Hour Sleep-Wake Disorder

Interventions

  • tasimelteonDrug

    20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment-Emergent Adverse Events (AEs)Time frame: 24 months + 12 month optional extension

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Pulmonary Associates, PA

    Phoenix, Arizona

  • SDS Clinical Trials Inc.

    Orange, California

  • VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area)

    Palo Alto, California

  • St. Johns Sleep Disorder Center - St. Johns Medical Plaza

    Santa Monica, California

  • Radiant Research - Denver

    Denver, Colorado

  • PAB Clinical Research Inc.

    Brandon, Florida

  • Kendall South Medical Center, Inc.

    Miami, Florida

  • Neurology Associates of Ormond Beach

    Ormond Beach, Florida

  • Sleep Disorders Center Of Georgia

    Atlanta, Georgia

  • Suburban Lung Associates SC (Chicago Metropolitan Area)

    Elk Grove Village, Illinois

  • The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area)

    Chevy Chase, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Michigan Head-Pain Neurological Institute

    Ann Arbor, Michigan

  • St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area)

    Chesterfield, Missouri

  • New York Eye and Ear Infirmary

    New York, New York

  • Ohio Sleep Medicine Institute (Columbus Metropolitan Area)

    Dublin, Ohio

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Columbia Research Group Inc.

    Portland, Oregon

  • Center for Sleep Medicine at Chestnut Hill Hospital

    Philadelphia, Pennsylvania

  • Consolidated Clinical trials

    Pittsburgh, Pennsylvania

  • SleepMed, Inc. - Columbia

    Columbia, South Carolina

  • Todd J. Swick, M.D., P.A.

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.